Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now ...

New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic advantages for Purple Biotech’s lead immunotherapy candidate as it advances toward ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’ The medical device maker gave ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...